Age-Related Macular Degeneration

New Course Helps Eyecare Practitioners to Upskill and keep up to date with latest research results on age-related macular degeneration.

There have been significant advances in the diagnosis and management of age-related macular degeneration (AMD) in the past few years. AMD is the most common cause of vision impairment in people over the age of 50 years, affecting almost 200 million people worldwide. Primary health practitioners, such as optometrists, are often the first professionals to detect the signs and symptoms of AMD. As such, it is essential that they are up to date with the latest information on imaging biomarkers, risk prediction and management of people with AMD.

Age-Related Macular Degeneration

This e-learning course provides an evidence-based update for practicing clinicians, trainees and students. The course will upskill you on the use of new imaging tools, the interpretation of novel clinical biomarkers, and the use of visual assessments in the clinic. It will focus on improving your patient management, including information on how to advise people with AMD on the newest emerging treatments and technologies that could improve their quality of life.

Designed for:

This course is suitable for primary eyecare practitioners, particularly optometrists. It may also be of interest to general practitioners, ophthalmic nurses and orthoptists.

Learning outcomes:

  1. Learn the latest imaging biomarkers for the detection and monitoring of age-related macular degeneration (AMD), specifically using optical coherence tomography.
  2. Understand the latest theories on the pathogenesis of AMD, and the correlations between clinical signs and symptoms and retinal changes evident on histopathology.
  3. Use evidence-based guidelines for the assessment and management of AMD.
  4. Be able to interpret ocular images to determine individual risk profiles and best management strategies and counselling for patients.
  5. Develop an understanding of current and emerging treatments for early stages of disease, as well as late-stage AMD, including anti-VEGF injections, stem cells and gene therapy.

Course outline:

8 tutorials
10 case studies
10 hours of eLearning
A Certificate of Completion provided upon satisfactory completion of the course

For more information, visit go.unimelb.edu.au/xk3r